| Year |
Citation |
Score |
| 2022 |
Gazarian D, Addis ME, Jampel JD, Hoffman E. Contexts of Concealment: Initial Validation of Three Disclosure Avoidance Process Measures. Journal of Personality Assessment. 1-17. PMID 35787067 DOI: 10.1080/00223891.2022.2085110 |
0.559 |
|
| 2019 |
Jampel JD, Gazarian D, Addis ME, Hoffman E. Traditional Masculinity Ideology and Diagnostic Aversion Predict Symptom Expression in a Community Sample of Distressed Men Sex Roles. 82: 704-715. DOI: 10.1007/S11199-019-01083-3 |
0.572 |
|
| 2017 |
Zimmerman M, Gazarian D, Multach M, Attiullah N, Benoff T, Boerescu DA, Friedman MA, Mehring LB, Moon S, Patel S, Holst CG. A clinically useful self-report measure of psychiatric patients' satisfaction with the initial evaluation. Psychiatry Research. 252: 38-44. PMID 28242516 DOI: 10.1016/J.Psychres.2017.02.036 |
0.476 |
|
| 2016 |
Zimmerman M, Multach MD, Clark HL, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in late life depression antidepressant efficacy trials. International Journal of Geriatric Psychiatry. PMID 27546477 DOI: 10.1002/Gps.4560 |
0.487 |
|
| 2016 |
Zimmerman M, Holst CG, Clark HL, Multach M, Walsh E, Rosenstein LK, Gazarian D. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years. Cns Drugs. PMID 27541608 DOI: 10.1007/S40263-016-0381-0 |
0.551 |
|
| 2016 |
Gazarian D, Multach MD, Ellison WD, Chelminski I, Dalrymple K, Zimmerman M. Does 'fear of dying' indicate a more severe presentation of panic disorder? Journal of Anxiety Disorders. 40: 52-57. PMID 27105467 DOI: 10.1016/J.Janxdis.2016.04.005 |
0.577 |
|
| 2016 |
Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Variability in the substance use disorder exclusion criterion in antidepressant efficacy trials. Journal of Affective Disorders. 198: 39-42. PMID 27002283 DOI: 10.1016/J.Jad.2016.03.024 |
0.5 |
|
| 2016 |
Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Symptom Severity and the Generalizability of Antidepressant Efficacy Trials: Changes During the Past 20 Years. Journal of Clinical Psychopharmacology. PMID 26848791 DOI: 10.1097/Jcp.0000000000000466 |
0.537 |
|
| 2016 |
Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. Cns Drugs. PMID 26818632 DOI: 10.1007/S40263-016-0314-Y |
0.482 |
|
| 2015 |
Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. Journal of Affective Disorders. 190: 357-361. PMID 26546771 DOI: 10.1016/J.Jad.2015.10.041 |
0.546 |
|
| 2015 |
Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Have Treatment Studies of Depression Become Even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published During the Past 20 Years. Mayo Clinic Proceedings. 90: 1180-6. PMID 26276679 DOI: 10.1016/j.mayocp.2015.06.016 |
0.47 |
|
| 2015 |
Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Have Treatment Studies of Depression Become even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published during the Past 20 Years Mayo Clinic Proceedings. 90: 1180-1186. DOI: 10.1016/j.mayocp.2015.06.016 |
0.473 |
|
| 2014 |
Zimmerman M, Gazarian D. Is research on borderline personality disorder underfunded by the National Institute of Health? Psychiatry Research. 220: 941-4. PMID 25446463 DOI: 10.1016/J.Psychres.2014.09.021 |
0.415 |
|
| Show low-probability matches. |